Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1428 - 1428
Published: Nov. 9, 2024
The development of therapies targeting unregulated Src signaling through selective kinase inhibition using small-molecule inhibitors presents a significant challenge for the scientific community. Among these inhibitors, pyrazolo[3,4-
Language: Английский
European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 970, P. 176484 - 176484
Published: March 11, 2024
Language: Английский
Citations
11
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 21, 2025
Abstract Aging is an inevitable physiological process in organisms, and the development of tumors closely associated with cellular senescence. This article initially examines role senescence tumorigenesis, emphasizing correlation between telomere length—a marker senescence—and tumor risk. Concurrently, study explores expression levels senescence-associated markers, such as p16, p53, mTOR, context development. Additionally, investigates impact on organismal senescence, including effects immune system function metabolic processes. Ultimately, discussion potential application anti-aging strategies therapy considers possibility utilizing mechanisms a novel therapeutic approach for tumors. research provides insights into complex interplay development, suggesting future preventative measures interventions.
Language: Английский
Citations
0
International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125504 - 125504
Published: March 1, 2025
Language: Английский
Citations
0
Nanotechnology Reviews, Journal Year: 2025, Volume and Issue: 14(1)
Published: Jan. 1, 2025
Abstract Osteosarcoma (OS) is the most frequent primary malignant bone tumor in adolescents and young adults. Despite advances therapy, OS remains an ominous problem because of its high metastatic potential, resistance to standard great physical, psychological, financial burden on patients. Available treatment options like surgery high-dose chemotherapy are limited by chemotoxicity, multimed resistance, adverse effects quality life Extrapolated from wide array vitro vivo studies, application kinase inhibitors targeting oncogenic signaling pathways, such as insulin-like growth factor 1 receptor, PDGFR, PI3K/AKT/mTOR pathway, appears quite promising. However, patients plagued with challenges poor bioavailability, off-target effects, mechanisms, which prevent clinical application. This review explores how nanotechnology beginning meet these challenges. Liposomes, polymeric nanoparticles, metallic nanoparticles among that provide new solutions for delivery bioavailability inhibitors, reducing systemic toxicity enhancing therapeutic accuracy. Active or passive enabled nanocarriers, enable drugs specifically act tissues while minimizing healthy cells. Additionally, diagnostic functionalities combined into theranostic platforms through pave way personalized medicine approaches. Nanoparticle-based have shown efficacy preclinical setting overcome drug improve targeting, sustained release drug. These dramatic improving outcomes at much less than currently available treatments. shows need further exploration bridge exciting findings practice. Future studies should seek optimize nanoparticle design evade enhance target specificity, reduce time-dependent toxicity. Further, incorporation a strategy has possibility changing treated bringing promise better patient life.
Language: Английский
Citations
0
Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(9)
Published: Sept. 1, 2024
Language: Английский
Citations
2
Journal of the American Chemical Society, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 17, 2024
Photoaffinity labeling is a widely used technique for studying ligand-protein and protein-protein interactions. Traditional photoaffinity labels utilize nonspecific C-H bond insertion reactions mediated by highly reactive intermediate. Despite being the most labels, diazirines exhibit limited compatibility with downstream organic suffer from storage stability concerns. This study introduces oxadiazolines as innovative complementary photoactivatable addition to toolbox demonstrates their application in vitro through
Language: Английский
Citations
2
Microchemical Journal, Journal Year: 2024, Volume and Issue: unknown, P. 112436 - 112436
Published: Dec. 1, 2024
Citations
1
Bioorganic & Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 115, P. 130018 - 130018
Published: Nov. 12, 2024
Language: Английский
Citations
0
Published: Dec. 8, 2024
Background Metabolic reprogramming has emerged as a key hallmark of cancer progression, though its role in tumor aggressiveness is still evolving. Here, using pan-cancer genome approach, we aimed to comprehensively assess the metabolic involved carcinomas and identify hubs which can be therapeutically targeted treat aggressive tumors clinic. Methods In this study, employed stringent multi-omic metabolism-targeted differential expression approach regulating aggressiveness. mRNA, miRNA, DNA methylation mutation profiling data representing 14 different types was downloaded from TCGA database. Cell line drug response CCLE Pathway enrichment, GSEA, String protein-protein interaction, miRNA-mRNA prediction, network random-walk analyses were carried out. Results We identified downregulated enzymes oxidative phosphorylation common factor across carcinomas, aligning with Warburg effect. Additionally, established that decreased dependence on driven by elevated miR-199 family miRNAs inhibit their at post-transcriptional level. Furthermore, epithelial-to-mesenchymal transition-related transcription factor, TWIST1, master regulator controlling miR-199a-3p -5p expression. Random walk analysis NDUFA2, DLD, COX15, NDUFB5, TIMM13 crucial become aggressive. Drug suggested targeting PDGFR signaling may offer novel therapeutic counteract loss phosphorylation. Conclusion TWIST1/miR-199a axis mediated suppression major contributor towards carcinomas. These insights underscore critical interplay between aggressiveness, opening avenues for potential therapies clinical settings.
Language: Английский
Citations
0
International Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 21(8), P. 1461 - 1471
Published: Jan. 1, 2024
Dasatinib is one of the second-generation tyrosine kinase inhibitors used to treat chronic myeloid leukemia and has a broad target spectrum, including KIT, PDGFR, SRC family kinases. Due its drug dasatinib been reported at basic research level improve athletic performance by eliminating senescent cell removal have an effect on muscle diseases such as Duchenne muscular dystrophy, but myoblasts not investigated. In this study, we evaluated effects skeletal both under normal conditions in regenerating state. suppressed proliferation promoted fusion C2C12 myoblasts. During regeneration, increased gene expressions myogenic-related genes (
Language: Английский
Citations
0